P38 MAP Kinase Inhibitors for Osteoarthritis Treatment
Author Information
Author(s): Kimberly K Brown, Sandra A Heitmeyer, Erin B Hookfin, Lily Hsieh, Maria Buchalova, Yetunde O Taiwo, Michael J Janusz
Primary Institution: Procter & Gamble Pharmaceuticals, Inc.
Hypothesis
The study evaluates the potential role of p38 inhibitors for the treatment of osteoarthritis using an animal model.
Conclusion
P38 inhibitors SB203580 and VX-745 may be effective in reducing both cartilage degeneration and pain associated with osteoarthritis.
Supporting Evidence
- Both SB-203580 and VX-745 significantly inhibited joint degeneration in the rat model.
- The drugs also significantly reduced pain response in the Hargraeves hyperalgesia assay.
- Inhibition of TNF release from LPS stimulated human cells was observed with both inhibitors.
Takeaway
Researchers tested two drugs on rats to see if they could help with joint pain and damage from arthritis, and they found that the drugs worked well.
Methodology
The study used an animal model of joint degeneration induced by iodoacetate and assessed the effects of p38 inhibitors on cartilage damage and pain response.
Participant Demographics
Sprague-Dawley male rats weighing 220–230 grams were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website